In a pivotal online policy debate hosted by the Geneva Global Health Hub (G2H2) in Switzerland and Corporate Accountability, global health leaders and civil society experts exposed the tobacco industry’s multifaceted campaign to reshape public health policy, targeting youth and infiltrating new sectors.
The session, titled: From Harm Reduction to Corporate Capture: How Tobacco Industry Marketing and Pharmaceutical Acquisitions are Reshaping Public Health Policy, highlighted urgent threats as the World Health Organization’s Executive Board prepares to meet.
Africa: A Replacement Market for Big Tobacco
Sarah Ekwale of Corporate Accountability and Public Participation Africa (CAPPA) detailed how the industry is aggressively targeting African youth. “While tobacco use declines globally, Africa is treated as the industry’s replacement market,” Ekwale stated. She outlined predatory tactics including flavored products, social media marketing via influencers and music festivals, point-of-sale promotion near schools, and even the deceptive marketing of lung cleanser products that falsely promise to reverse smoking damage. “Big Tobacco’s appeal is not organic; it is manufactured through a system of deception and addiction,” she concluded.
Pharmaceutical Takeovers: A Bid for Legitimacy
Professor Nicholas Hopkinson of Imperial College London and ASH UK presented an alarming case study: the 2021 acquisition of inhaler company Vectura by Philip Morris International (PMI). He explained this move as an attempt to diversify, launder the company’s reputation, and own the technology for nicotine delivery. A concerted boycott by health professionals, medical societies, and patients, who refused to use inhalers funding the tobacco industry, ultimately made the venture untenable. PMI sold Vectura in 2024 at a loss of nearly £1 billion. “The lesson is vigilance and a clear, systematic rejection of the tobacco industry in all its forms,” said Prof. Hopkinson. “We must reject the two-industry narrative there is no good company separate from the one that kills a million people a year.”
Hijacking Harm Reduction to Sell Addiction
Bobby Ramakant, of the Network for Accountability of Tobacco Transnationals, warned that the industry is abusing the concept of harm reduction to undermine the WHO Framework Convention on Tobacco Control (FCTC). “They are dishing out their own junk science and using words like innovation and technovation to masquerade deadly nicotine products,” he said. Ramakant cited examples of PMI flying journalists to events in South Africa, Indonesia, and the UAE to promote this narrative. He emphasized that declines in smoking are due to strong FCTC implementation, not industry products.
Safeguarding Policy with Article 5.3
Florencia Leiva of the Coalition for America’s Health (CLAS) focused on how the industry’s reframing of harm reduction seeks to re-enter policy debates. She pointed to the recent COP11 meeting on the FCTC, where discussions on protecting policies from commercial interests were derailed by delegations parroting industry talking points. “This is why Article 5.3 of the FCTC is more crucial than ever,” Leiva asserted. “It is the cornerstone for protecting public health policy from an industry whose interests are irreconcilable with human health.” She called for the principle to be extended across the UN system and WHO governance.
A Call for Proactive Defense
In closing remarks, Jaime Arcila of Corporate Accountability synthesized the panel’s findings: “Predatory marketing, pharmaceutical acquisitions, and the hijacking of harm reduction are all facets of a single strategy: corporate capture. Article 5.3 is our backbone for defense. We must move from a defensive posture to a proactive one, prioritizing public health over industry profits everywhere.”
The panel called on governments, especially in targeted regions like Africa, to fully implement the FCTC, ban all forms of marketing (including digital), increase tobacco taxes, and empower youth-led advocacy to counter industry manipulation.
Share this
